source
- Intercept’s next-generation FXR agonist INT-787 fails Phase 2 trial in alcohol-associated hepatitisIntercept Pharmaceuticals reported that its experimental FXR agonist INT-787 did not demonstrate efficacy in a Phase 2 study of patients with severe alcohol-associated hepatitis. The trial results…
- Celcuity reports positive Phase 3 results for gedatolisib in PIK3CA-mutant breast cancerOn May 4, 2026 Celcuity announced that its experimental drug gedatolisib achieved success in two treatment regimens for patients whose tumors carry PIK3CA mutations, according to data from its ongo…